Ovarian Cancer: Affordable Care Act Increased Early Diagnosis

According to researchers, expanded access to health insurance as a result of the implementation of the 2010 Affordable Care Act (ACA) led to earlier diagnosis and treatment of ovarian cancer. For the study, results of which were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, the investigators used a difference-in-differences approach to compare stage at diagnosis and time to treatment before and after the ACA between two groups of women with ovarian cancer: th...
Continue reading

New Targets Identified in BRCA-Mutated Cancers

Researchers at Brigham and Women's Hospital have identified two new genes that can impact BRCA2-deficient cancer through "synthetic lethality," which occurs when a combination of deficiencies in two or more genes leads to cell death that would not occur with one deficiency alone. Inactivation of BRCA1 or BRCA2, both important tumor suppressor genes named for their roles in breast cancer, increases a woman's risk of breast cancer by up to 80% and increases her risk of ovarian cancer by around 50%...
Continue reading

PTUPB: A Key to Hindering Tumor Inflammation

Although chemotherapy is a potent treatment, it sometimes causes dying cancer cells to become inflamed, triggering the growth of more malignant cells. Researchers have discovered a new anti-inflammatory compound that decreases tumor inflammation and reduces cancer growth in ovarian tumors in mice. In these recent developments, published in Proceedings of the National Academy of Sciences, investigators discovered that first-line platinum- and taxane-based chemotherapies fuel a macrophage-derived ...
Continue reading

Current Challenges and Promising Advances in Recurrent Ovarian Cancer With Ursula Matulonis, MD

Ovarian cancer accounts for 5% of cancer deaths among women in the United States and causes more deaths than any other cancer of the female reproductive system. An estimated 22,240 new cases are diagnosed annually, and 14,070 people die of the disease. Relative survival varies by age; women younger than 65 are much more likely to survive 5 years (77%) following diagnosis than women 65 and older (20%). Overall, the 5-year relative survival rate for ovarian cancer patients is 47%. If diagnosed at ...
Continue reading

Advanced Gynecologic Cancers: Olaparib Approved for Maintenance Therapy

The FDA has now approved olaparib (Lynparza®, AstraZeneca Pharmaceuticals LP) for maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer experiencing complete or partial response to first-line platinum-based chemotherapy. Patients are to be selected for therapy using an FDA-approved companion diagnostic, the BRACAnalysis CDx® test (Myriad Genetic Laboratories, Inc.). The ...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.